Edit Reading

Back to List

Basic Information

Title

Please enter a title.

URL

Please enter a valid URL.

Date

カテゴリID

画像ファイル名

統計情報

単語数: 197語

読了回数: 0回

作成日: 2023/08/08 20:36

更新日: 2025/12/09 01:13

本文

Wegovy shown to reduce risk of heart attack, stroke in major cardiovascular trial
By Meg Tirrell, CNN
2 minutes ago

wegovy limits 052023
The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart disease-related death by 20% in a major clinical trial in people with cardiovascular disease, the first to show a weight loss drug alone can have such protective effects.

Novo Nordisk studied Wegovy against placebo in addition to standard of care for prevention of major adverse cardiac events in 17,604 adults with heart disease and obesity or who were overweight, but who didn't have diabetes. It called the trial "Select."

The finding of a 20% reduction in heart risk is higher than many experts had anticipated. A similar trial for the type 2 diabetes drug Ozempic, which uses the same ingredient, semaglutide, previously showed it could reduce cardiovascular risk by 26% - but no trial had yet shown a risk reduction in people without diabetes.

"Select is a landmark trial and has demonstrated that semaglutide 2.4mg has the potential to change how obesity is regarded and treated," said Martin Holst Lange, Novo Nordisk's executive vice president for development.

本文を入力してください。

メモ

メモ・感想

キャンセル

Edit Reading

Basic Information

統計情報

本文

メモ

Send Report